BI weighs sale of generic business

Boehringer Ingelheim is considering the sale of Roxane Labs, a unit of its US- based generic business, Reuters reported Thursday. The drugmaker said in a statement thats it is currently deciding the future of the Columbus, Ohio-based business. A company spokesperson told the news service that BI is weighing a sale because it is not a specialist in the generics space. Bloomberg reported that Roxane Labs could be worth up to $2.36 billion.